去纤苷治疗肝小静脉闭塞病效果好吗？

On October 22, 2013, Defitelio (defibrotide sodium) was approved for marketing by the European Union as the first treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation. On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defitelio (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) caused by hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction. Defibrotide is the first and only drug for the treatment of severe hepatic veno-occlusive disease.  

Hepatic veno-occlusive disease (HVOD), also known as sinusoidal obstruction syndrome, is a non-thrombotic obstruction of the hepatic circulation, accompanied by centrilobular sinusoidal fibrosis and fibrotic stenosis or occlusion of common hepatic venules. Clinical manifestations include liver enlargement, pain, ascites, etc., and more than half of the patients can recover. 20% of patients die of liver failure, and a few patients develop cirrhosis and portal hypertension.

The mechanism of action of defibrotide has not been fully elucidated. In vitro, defibrinoside enhances the enzymatic activity of plasmin that hydrolyzes fibrin clots. Studies evaluating the pharmacological effects of defibrinated sodium on endothelial cells (ECs) have been primarily conducted in human microvascular endothelial cell lines. In vitro, defibrinoside increases tissue plasminogen activator (t-PA) and thrombomodulin expression and decreases von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) expression, thereby reducing EC activation and increasing EC-mediated fibrinolysis. Defibrotide protects ECs from chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion-induced injury. 

The above is the therapeutic effect of defibrotide (sodium defibrination) provided by our medical companion overseas medical consulting service company. The therapeutic effect of defibrination (sodium defibrination) is considerable, so many patients choose defibrination (sodium defibrination).